Big pharma, Partnering, Pharma

Merck KGaA returns Sym004 to Symphogen

Posted on 02 February 2015

Tags: , , ,

Merck KGaA is conducting an ongoing assessment of its pipeline assets and has decided to return the rights of Sym004 to Symphogen for further development.

The decision to return the rights is not related to any new safety or efficacy findings regarding Sym004.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time


The regained Sym004 product rights provide Symphogen with a valuable opportunity to retain the value of this attractive clinical candidate, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR), currently in Phase 2b and 1b trials.

For further deal information visit Current Agreements (subscription required)


Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply